The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study

HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial

(2013) Mariette I E van Poelgeest et al.   Journal of Translational Medicine

A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions

(2012) Peggy J. de Vos van Steenwijk et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: A phase I/II clinical trial

(2012) Eliane C.M. Zeestraten et al.   INTERNATIONAL JOURNAL OF CANCER

Therapeutic vaccination against human papilloma virus induced malignancies

(2011) Sjoerd H van der Burg et al.   CURRENT OPINION IN IMMUNOLOGY

A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen

(2011) Kazuhiro Kakimi et al.   INTERNATIONAL JOURNAL OF CANCER

Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia

(2010) S Daayana et al.   BRITISH JOURNAL OF CANCER

Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond

(2010) C. M. Britten et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Phase 1 Trial of Wilms Tumor 1 (WT1) Peptide Vaccine and Gemcitabine Combination Therapy in Patients With Advanced Pancreatic or Biliary Tract Cancer

(2010) Miho Kaida et al.   JOURNAL OF IMMUNOTHERAPY

Immunization with Cocktail of HIV-Derived Peptides in Montanide ISA-51 Is Immunogenic, but Causes Sterile Abscesses and Unacceptable Reactogenicity

(2010) Barney S. Graham et al.   PLoS One

Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses

(2010) M. J. P. Welters et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

“MIATA”—Minimal Information about T Cell Assays

(2009) Sylvia Janetzki et al.   IMMUNITY

Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia

(2009) Gemma G. Kenter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine

(2008) M. J.P. Welters et al.   CLINICAL CANCER RESEARCH

Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity

(2008) G. G. Kenter et al.   CLINICAL CANCER RESEARCH

Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51

(2008) Yimin Wu et al.   PLoS One